EUCTR2016-002257-37-FR进行中（未招募）1 期
Secured access to nivolumab for adult patients with selected rare cancer types - AcSé Nivolumab
ICANCER0 个研究点开始时间: 2017年2月17日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Patient information sheet and written informed consent (PIS/ICF) form signed.
- •2. Histologically confirmed diagnosis of a pathology corresponding to one of the following selected cancer types:
- •Non-clear cell renal-cell carcinomas: papillary renal cell carcinoma (pRCC, type I, type II and non-classified pRCC), chromophobe RCC (ChRCC), renal medullary carcinoma (RMC), collecting duct/Bellini duct carcinoma (CDC), microphthalmia-associated transcription (MiT) family translocation renal cell carcinoma (tRCC), renal cell carcinoma with a prominent sarcomatoid component (sarcRCC).
- •Rare head and neck cancers: principal and accessory salivary gland tumours, facial tissue tumours.
- •Rare skin cancers: adnexal carcinomas, basal cell carcinoma resistant to vismodegib.
- •Non-colorectal cancers with microsatellite instability determined locally by immunohistochemistry or polymerase chain-reaction (PCR)
- •Squamous cell carcinoma of penis.
- •3. Metastatic disease or unresectable locally advanced malignancy that is resistant or refractory to standard therapy or for which standard therapy does not exist or is not considered appropriate by the Investigator.
- •4. Aged = 18 years old.
- •5. Measurable disease according to RECIST v1.1 guidelines for solid tumours (Eisenhauer, 2009; Appendix 1).
- •6. Able to provide a FFPE biopsy sample of a metastatic site or primitive tumour tissue.
- •Note: Patients for whom suitable archived biopsy material is not available must be willing to undergo a biopsy of a tumour lesion prior to study entry, unless this is medically contraindicated (e.g. site inaccessible or patient safety concerns).
- •7. Patients must have a mandatory treatment-free interval of at least 21 days following previous systemic anti-cancer treatments.
- •8. Patients who have received previous systemic anticancer treatment and/or radiotherapy should have recovered from any treatment related toxicity, to a level of = grade 1 (according to NCI-CTCAE criteria, v 4.0, Appendix 2) with the exception of Grade 2 alopecia.
- •9. Adequate hematologic function (absolute neutrophil count [ANC] = 1.0 x109/L, platelets = 100 x109/L, haemoglobin (Hb) = 9 g/L) measured within 14 days of treatment initiation.
- •10. Adequate renal function (creatinine clearance = 50 mL/ using the MDRD or CKI EPI method) measured within 14 days of treatment initiation.
- •11. Adequate hepatic function (serum bilirubin = 1.5 x the reference upper limit of normal (ULN) unless due to Gilbert’s syndrome; aspartate aminotransferase [ASAT] and alanine aminotransferase [ALAT] = 2,5 xULN) measured within 14 days of treatment initiation. For patients with documented liver metastasis ASAT/ALAT = 5x ULN is acceptable.
- •12. Strictly normal blood levels of calcium and magnesium, measured within 14 days of treatment initiation.
- •13. Eastern Cooperative Oncology Group (ECOG) Performance Status of = 1 (Oken, 1982; Appendix 3).
- •14. Estimated life expectancy = 90 days.
- •15. Patients who are sexually active must agree to use a medically accepted method of contraception (e.g. implants, injectables, combined oral contraceptives, some intrauterine devices or vasectomized partner, for participating women; condoms for participating men) or practice complete abstinence, beginning 14 days before the first administration of IP, while on treatment and for at least 5 months after the last administration of IP for female patients, and 7 months after the last administration of IP for male patients.
- •16. Women of childbearing potentia
排除标准
- •1. Prior treatment with an anti-PD1 or anti-PD-L1 antibody
- •2. Eligible, and willing, to participate in a clinical trial of an alternative anticancer therapy targeting their disease which is open to accrual in France.
- •3. Concurrent steroid medication at a dose greater than prednisone 10 mg/day or equivalent (Appendix 4).
- •4. Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
- •5. History of (non-infectious) pneumonitis that required steroids, or current pneumonitis.
- •6. History of severe hypersensitivity reaction to any monoclonal antibody therapy
- •7. Radiotherapy (except for brain and extremities) within 21 days prior to the first administration of IP.
- •8. Treatment with other investigational drugs or participation in another clinical trial within 21 days prior to the first administration of IP or concomitantly with the trial.
- •9. Has known symptomatic central nervous system (CNS) metastases. Patients with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging for at least four weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for at least 7 days prior to trial treatment.
- •10. Has known carcinomatous meningitis or a history of leptomeningeal disease.
- •11. Serum creatinine > 1.5 xULN or glomerular filtration rate (GFR) < 50 ml/min.
- •12. Lymphocytes count below 1,000/mm3 and CD4+ count below 500/mm3 as assessed by routine blood phenotyping.
- •13. Other malignancies within the past 5 years other than basal cell skin cancer or carcinoma in situ of the cervix.
- •14. Active serious infections in particular if requiring systemic antibiotic or antimicrobial therapy.
- •15. Active or chronic hepatitis B, hepatitis C and/or human immunodeficiency virus (HIV) infection (HIV 1/2 antibodies), or a known history of active Tuberculosis bacillus.
- •16. Has received a live vaccine within 30 days of planned start of study treatment.
- •Note: Seasonal influenza vaccines for injection are generally inactivated vaccines and are allowed; however intranasal influenza vaccines (e.g. Flu-Mist®) are live attenuated vaccines, and are not allowed.
- •17. Active alcohol or drug abuse.
- •18. Psychological, familial, sociological or geographical factors potentially hampering compliance with the study protocol and follow-up schedule.
- •19. Any condition which in the Investigator’s opinion makes it undesirable for the subject to participate in the trial or which would jeopardize compliance with the protocol.
研究者
相似试验
已完成
2 期
Secured Access to Nivolumab for Adult Patients With Selected Rare Cancer TypesCarcinoma, Renal CellHead and Neck NeoplasmSkin NeoplasmsMicrosatellite InstabilityPenile NeoplasmsCancer With POLE Exonucleasic Domain MutationNCT03012581UNICANCER269
招募中
2 期
Phase 2 Study Assessing Secured Access to Vemurafenib for Patients With Tumors Harboring BRAF Genomic Alterations2024-514904-14-00Unicancer, Unicancer50
进行中（未招募）
1 期
_Patients with unresectable locally advanced or metastatic, rare soft tissue sarcoma, visceral sarcoma, or bone sarcoma, rare ovarian cancer, primary central nervous system lymphomas (PCNSL), rare thyroid cancer, rare malignant neuroendocrine cancer or germ-cell cancer, which is resistant or refractory to standard therapy, or for which standard therapy does not exist, or is not considered appropriate, and for which no other experimental treatment options are available.EUCTR2016-002260-14-FRICANCER
No Longer Available
不适用
Expanded Access Program With Nivolumab Therapy for Treatment of Advanced/Metastatic SqNSCLC or Non-SqNSCLC After One Prior Systemic RegimenSquamous Non-Small Cell Lung CancerNon-squamous Non-Small Cell Lung CancerNCT02475382Bristol-Myers Squibb
尚未招募
不适用
EXPANDED ACCESS PROGRAM WITH NIVOLUMAB FOR SUBJECTS WITH HISTOLOGICALLY CONFIRMED STAGE III (UNRESECTABLE) OR STAGE IV MELANOMA PROGRESSING POST PRIOR SYSTEMIC TREATMENT CONTAINING AN ANT-CTLA-4 MONOCLONAL ANTIBODY.-C439 Malignant melanoma of skin, unspecifiedMalignant melanoma of skin, unspecifiedC439PER-012-15BRISTOL MYERS SQUIBB COMPANY,